Filters

 

Resource Type
Assays capable of detecting TRPML1 modulators for drug discovery

We generated a stable cell line expressing the lysosomal channel TRPML1 at the cell surface. First we validated this on manual patch-clamp and went on to develop robust assays for our higher throughput screening platforms, Qube 384 and FLIPR Penta, which are capable of detecting TRPML1 modulators for drug discovery.

Read More
Metrion Biosciences enhances high-throughput screening services with access to Enamine compound libraries
Read More
Metrion Biosciences strengthens team with 3 key appointments
Read More
Metrion Biosciences closes £3.7m new equity financing
Read More
Metrion Biosciences announces launch of Good Laboratory Practice (GLP) hERG Testing Service
Read More
Metrion Biosciences expands senior leadership team with appointments of Dr Robert Kirby as COO and Dr Edward Stevens as CSO
Read More
Metrion Biosciences appoints Dr Steve Jenkinson as VP, Drug Discovery and Safety Assessment to strengthen US Operations
Read More
Metrion Biosciences and the KCNC1 Foundation collaborate on development of new ion channel modulators for ultra-rare genetic disorder
Read More
Metrion Biosciences invests in new High Throughput Screening capability and expanded facilities
Read More
Metrion Biosciences appoints Dr Benedetta Montagnini as head of European Business Development
Read More
Metrion Biosciences

Let’s work together

If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.
Contact us for a quote or discussion
Metrion Biosciences is a contract research organisation (CRO) specialising in high-quality preclinical drug discovery services.
magnifier
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram